Payment overview · 2025
General Payments
$1,440.58
65 reported records · 16 companies
Healthcare provider profile · identity verified
Michele Hernandez, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HOUSTON, TX · NPI 1982954541
Verified facts
What the public records show
CMS Open Payments records show Michele Hernandez, NP received $1,440.58 in general payments during 2025 across 65 reported records.
Novo Nordisk Inc accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $268.07 | 18.6% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $209.17 | 14.5% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $206.53 | 14.3% | 17 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $123.78 | 8.6% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $123.00 | 8.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $119.87 | 8.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $78.67 | 5.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $68.98 | 4.8% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.98 | 4.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.34 | 3.1% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $39.60 | 2.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.62 | 2.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.73 | 1.4% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.44 | 1.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.00 | 1.2% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $13.80 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,440.58 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $209.17 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $201.00 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $183.68 | 8 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $123.78 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $123.00 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $119.87 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $119.62 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $89.30 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $86.91 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $78.67 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $68.98 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $57.98 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $57.77 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.34 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.33 | 6 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $39.60 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $39.60 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $39.60 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.62 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
29 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 263 | 98 |
| Lisinopril | Lisinopril | 175 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 157 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 156 | 43 |
| Metformin Hcl | Metformin Hcl | 148 | 54 |
| Losartan Potassium | Losartan Potassium | 143 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 130 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 70 |
| Farxiga | Dapagliflozin Propanediol | 110 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 34 |
| Gabapentin | Gabapentin | 85 | 38 |
| Montelukast Sodium | Montelukast Sodium | 80 | 31 |
| Ozempic | Semaglutide | 76 | 21 |
| Baclofen | Baclofen | 75 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 71 | 29 |
| Famotidine | Famotidine | 69 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 23 |
| Carvedilol | Carvedilol | 65 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 46 |
| Trazodone Hcl | Trazodone Hcl | 59 | 16 |
| Azithromycin | Azithromycin | 58 | 55 |
| Simvastatin | Simvastatin | 57 | 18 |
| Metformin Hcl Er | Metformin Hcl | 56 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 19 |
| Furosemide | Furosemide | 55 | 22 |
| Jardiance | Empagliflozin | 48 | 17 |
| Omeprazole | Omeprazole | 48 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 13 |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Ciclopirox | Ciclopirox | 40 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 17 |
| Meloxicam | Meloxicam | 36 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 17 |
| Sertraline Hcl | Sertraline Hcl | 34 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | 16 |
| Meclizine Hcl | Meclizine Hcl | 31 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 27 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 29 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Allopurinol | Allopurinol | 27 | suppressed |
| Finasteride | Finasteride | 27 | 11 |
| Mupirocin | Mupirocin | 27 | 17 |
| Nifedipine Er | Nifedipine | 27 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 23 | 11 |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 19 |
| Fluconazole | Fluconazole | 21 | 16 |
| Linzess | Linaclotide | 21 | suppressed |
| Prednisone | Prednisone | 21 | 16 |
| Valsartan | Valsartan | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Nystatin | Nystatin | 16 | 13 |
| Ondansetron Odt | Ondansetron | 16 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Eliquis | Apixaban | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | 11 |
| Atenolol | Atenolol | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,440.58 · 65 records | Novo Nordisk Inc | AREXVY, BRIUMVI, CAPVAXIVE, CONTRAVE, Cologuard Collection Kit, FREESTYLE LIBRE 3, Flector, GARDASIL 9, INSPIRE, Kerendia, Licart, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, Tirosint, Tlando, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error